MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ChemoCentryx Company Profile (NASDAQ:CCXI)

Consensus Ratings for ChemoCentryx (NASDAQ:CCXI) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: N/A

Analysts' Ratings History for ChemoCentryx (NASDAQ:CCXI)
Show:
DateFirmActionRatingPrice TargetActions
5/19/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for ChemoCentryx (NASDAQ:CCXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/10/2016Q1($0.27)($0.34)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q4($0.28)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.29)($0.26)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.29)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.28)($0.28)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.28)($0.28)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014($0.28)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.24)($0.27)$0.38 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014($0.25)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2013Q2 2013($0.28)($0.23)$1.48 million$1.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q1 2013($0.27)($0.28)$2.04 million$1.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.28)$1.44 million$1.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for ChemoCentryx (NASDAQ:CCXI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for ChemoCentryx (NASDAQ:CCXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ChemoCentryx (NASDAQ:CCXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/23/2016James L TyreeDirectorSell5,544$4.39$24,338.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Thomas A EdwardsDirectorBuy50,000$4.05$202,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Thomas A EdwardsDirectorBuy25,000$4.05$101,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Geoffrey M ParkerDirectorBuy40,000$4.03$161,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016Susan M. KanayaCFOSell25,764$4.04$104,086.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016Susan M. KanayaCFOSell14,971$4.10$61,381.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Susan M. KanayaCFOSell6,134$4.05$24,842.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Susan M. KanayaCFOSell300$4.00$1,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Geoffrey M ParkerDirectorBuy20,000$4.63$92,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2016Susan M. KanayaCFOSell10,224$5.12$52,346.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Susan M. KanayaCFOSell47,607$6.98$332,296.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Susan M. KanayaCFOSell34,341$6.90$236,952.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Susan M. KanayaCFOSell10,490$7.38$77,416.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Geoffrey M ParkerDirectorBuy20,000$7.25$145,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Value Fund L P BiotechnologyInsiderSell360,000$7.00$2,520,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Value Fund L P BiotechnologyInsiderSell50,000$6.97$348,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Bvf Partners L P/IlMajor ShareholderSell955,700$9.00$8,601,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Ira KleinDirectorSell10,811$7.44$80,433.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Thomas J SchallCEOSell24,267$7.50$182,002.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2015Thomas J SchallCEOSell16,540$7.55$124,877.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Thomas J SchallCEOSell1,200$7.51$9,012.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Thomas J SchallCEOSell50,371$7.84$394,908.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Thomas J SchallCEOSell18,146$8.34$151,337.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Thomas J SchallCEOSell31,316$8.55$267,751.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Markus J CappelTreasurerSell34,125$7.81$266,516.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2015Markus J CappelTreasurerSell40,875$7.98$326,182.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2015Markus J CappelTreasurerSell5,943$7.81$46,414.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Markus J CappelTreasurerSell14,390$8.13$116,990.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Anne-Marie DuliegeEVPSell4,970$4.71$23,408.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Thomas J SchallCEOSell27,726$5.59$154,988.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2014Thomas J SchallCEOSell32,274$5.38$173,634.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Markus J CappelTreasurerSell20,962$8.17$171,259.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Thomas J SchallCEOSell20,000$7.25$145,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Geoffrey M ParkerDirectorBuy20,000$5.15$103,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Bvf Partners L P/IlMajor ShareholderBuy189,800$5.01$950,898.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2013Bvf Partners L P/IlMajor ShareholderBuy136,066$4.92$669,444.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy336,225$4.99$1,677,762.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2013Bvf Partners L P/IlMajor ShareholderBuy1,289,354$5.34$6,885,150.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013Bvf Partners L P/IlMajor ShareholderBuy109,425$5.49$600,743.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Bvf Partners L P/IlMajor ShareholderBuy325,635$5.95$1,937,528.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Joseph M FeczkoDirectorBuy10,000$6.03$60,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Markus J CappelTreasurerSell5,459$12.90$70,421.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2013Petrus BekkerSVPSell5,000$13.26$66,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Roger C LucasDirectorSell5,000$13.42$67,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Markus J CappelTreasurerSell6,250$13.82$86,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2013Markus J CappelTreasurerSell5,459$14.52$79,264.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2013Petrus BekkerSVPSell10,000$14.54$145,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2013Thomas J SchallCEOSell22,089$14.39$317,860.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Roger C LucasDirectorSell5,000$13.43$67,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Markus J CappelTreasurerSell6,250$13.88$86,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013Susan M KanayaCFOSell36,942$14.31$528,640.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2013Petrus BekkerSVPSell5,000$14.00$70,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Markus J CappelTreasurerSell6,250$13.00$81,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2013Markus J CappelTreasurerSell1,783$12.47$22,234.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Petrus BekkerSVPSell5,000$12.00$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Roger C LucasDirectorSell5,000$13.32$66,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2013Susan M KanayaCFOSell12,770$14.28$182,355.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Markus J CappelTreasurerSell3,676$14.10$51,831.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2013Petrus BekkerSVPSell4,800$14.00$67,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Petrus BekkerSVPSell15,000$13.97$209,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Markus J CappelTreasurerSell15,668$14.08$220,605.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Roger C LucasDirectorSell5,000$14.11$70,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Thomas J SchallCEOSell7,600$14.04$106,704.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2013Markus J CappelTreasurerSell1,500$14.10$21,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2013Petrus BekkerSVPSell3,979$14.03$55,825.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2013Thomas J SchallCEOSell2,529$14.02$35,456.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2013Petrus BekkerSVPSell11,502$13.98$160,797.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2013Thomas J SchallCEOSell5,541$14.01$77,629.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2013Roger C LucasDirectorSell5,000$13.87$69,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2013Juan C JaenSVPSell22,500$12.23$275,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2013Thomas J SchallCEOSell7,500$12.06$90,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2013Roger C LucasDirectorSell3,857$11.52$44,432.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2013Juan C JaenSVPSell3,875$11.69$45,298.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2013Markus J CappelTreasurerSell2,700$11.16$30,132.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2012Bvf Partners L P/IlMajor ShareholderBuy40,000$12.00$480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2012Roger C LucasDirectorSell1,893$11.47$21,712.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2012Susan M KanayaCFOSell3,971$11.89$47,215.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2012Thomas J SchallCEOSell15,000$11.53$172,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for ChemoCentryx (NASDAQ:CCXI)
DateHeadline
06/28/16 07:59 AMNext Weeks Broker Price Targets For ChemoCentryx, Inc. (NASDAQ:CCXI) - Fiscal Standard
06/24/16 05:25 AMStock to Keep Your Eyes on: ChemoCentryx, Inc. (CCXI) - iStreetWire
06/24/16 05:25 AMChemoCentryx, Inc. (NASDAQ:CCXI) Stock Momentum at Critical Inflection Point - CML News
06/19/16 03:00 PMChemoCentryx, Inc. (NASDAQ:CCXI) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 07:46 AMChemoCentryx Inc. (CCXI) Drops 9.94% on June 16 - Equities.com
06/16/16 09:17 AMChemoCentryx's lead product candidate shows positive results in mid-stage AAV study -
06/16/16 07:30 AMChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development - [GlobeNewswire] - --Safety study objective achieved: CCX168 shown to be well tolerated in patients with ANCA-associated vasculitis when added to current standard of care regimen--. --Initiation of Phase III development ...
06/15/16 07:55 AMRecently Issued Stock Ratings For ChemoCentryx, Inc. (NASDAQ:CCXI) - Fiscal Standard
06/08/16 11:39 AMChemoCentryx Inc. (CCXI) Jumps 6.3% on June 06 - Equities.com
06/07/16 08:45 PMCHEMOCENTRYX INC. (NASDAQ:CCXI) Financial Condition Compared to S&P 500 - CML News
06/06/16 01:26 PMChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/06/16 07:52 AMChemocentryx Incorporated (NASDAQ:CCXI) Shorted Shares Increased By 16.67% - HNN
06/04/16 11:39 AMCurrent Analysts Rating Update: ChemoCentryx, Inc. (NASDAQ:CCXI) , Genocea Biosciences, Inc. (NASDAQ:GNCA) - Street Updates
06/03/16 11:46 AMChemoCentryx Inc. (CCXI) is Trading Higher on Unusual Volume for May 31 - Equities.com
06/03/16 11:46 AMWatch-List HC Stocks: ChemoCentryx Inc (NASDAQ:CCXI), Cempra Inc (NASDAQ:CEMP) - share market updates (press release)
06/02/16 03:17 PMA Buy Signal for These Stocks: ChemoCentryx, Inc. (NASDAQ:CCXI), Waste Connections Inc. (NYSE:WCN) - Beacon Chronicle - Beacon ChronicleA Buy Signal for These Stocks: ChemoCentryx, Inc. (NASDAQ:CCXI), Waste Connections Inc. (NYSE:WCN)Beacon ChronicleChemoCentryx, Inc. (NASDAQ:CCXI) currently has High Price Target of $11. The Low and Mean Price Targets are $11 and $11 respectively. These price targets are a consensus analysis of 1 brokers. When having a look at Recommendation Trends of the ...and more »
06/01/16 09:16 PMChemoCentryx's (CCXI) CCX168 Receives EMA PRIME Designation as AAV Treatment - StreetInsider.com - The Point ReviewChemoCentryx's (CCXI) CCX168 Receives EMA PRIME Designation as AAV TreatmentStreetInsider.comChemoCentryx, Inc., (Nasdaq: CCXI) announced it received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for CCX168 for the treatment of ANCA-Associated Vasculitis, or AAV. As described by the EMA, PRIME aims to ...Stocks Under Consideration: CytRx (NASDAQ:CYTR), Ariad Pharmaceuticals, (NASDAQ:ARIA), ChemoCentryx ...The Point ReviewChemoCentryx Receives European Priority Medicines Designation for ANCA-Associated Vasculitis Treatment CCX168 ...Sonoran Weekly ReviewChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated ...Nasdaqall 5 news articles »
06/01/16 09:16 PMChemoCentryx Inc. (CCXI) Drops 7.98% on June 01 - Equities.com - ChemoCentryx Inc. (CCXI) Drops 7.98% on June 01Equities.comChemoCentryx Inc. (CCXI) was one of the Russell 2000's biggest losers for Wednesday June 01 as the stock slid 7.98% to $4.96, a loss of $-0.43 per share. Starting at an opening price of $5.56 a share, the stock traded between $4.77 and $5.60 over the ...and more »
06/01/16 03:14 PMBuy, Sell Or Hold Rating For ChemoCentryx, Inc. (NASDAQ:CCXI)? - Share Trading News - Buy, Sell Or Hold Rating For ChemoCentryx, Inc. (NASDAQ:CCXI)?Share Trading NewsChemoCentryx, Inc. has a 50 day moving average of 3.22 and a 200 day moving average of 4.39. The stock's market capitalization is 238.72M, it has a 52-week low of 1.92 and a 52-week high of 9.46. The share price of the company (NASDAQ:CCXI) was ...
06/01/16 03:14 PMAnalyst Rating Trends to Observe: Novavax, Inc. (NASDAQ:NVAX) , ChemoCentryx, Inc. (NASDAQ:CCXI) - Street Updates - Life Science DailyAnalyst Rating Trends to Observe: Novavax, Inc. (NASDAQ:NVAX) , ChemoCentryx, Inc. (NASDAQ:CCXI)Street UpdatesOn 5/31/2016, Novavax, Inc. (NASDAQ:NVAX) ended trading session higher at $6.09 with +3.92%. The company traded a volume of 9.04 million shares as comparison to average volume of 5.65 million shares. During the 52 –week period, the stock's price ...Current Analyst Rating: Novavax, Inc. (NASDAQ:NVAX), Novartis AG (NYSE:NVS)WsNews 4investorsall 10 news articles »
06/01/16 11:42 AMHC Stocks Momentum: ChemoCentryx Inc (NASDAQ:CCXI), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - share market updates (press release) - share market updates (press release)HC Stocks Momentum: ChemoCentryx Inc (NASDAQ:CCXI), Amicus Therapeutics, Inc. (NASDAQ:FOLD)share market updates (press release)Shares of ChemoCentryx Inc (NASDAQ:CCXI) ended Tuesday session in green amid volatile trading. The shares closed up +0.19 points or 3.65% at $5.39 with 3.50 million shares getting traded. Post opening the session at $5.19, the shares hit an intraday ...and more »
06/01/16 11:42 AMEarnings Report of the Stock: ChemoCentryx, Inc. (NASDAQ:CCXI), Invesco Ltd. (NYSE:IVZ) - Beacon Chronicle - Beacon ChronicleEarnings Report of the Stock: ChemoCentryx, Inc. (NASDAQ:CCXI), Invesco Ltd. (NYSE:IVZ)Beacon ChronicleLast Trade: The Company closed its last session at $5.39 with the gain of 3.65%. The market capitalization of the company is $202.93 Million, with the average Volume of 1.24 Million. The stock currently has its 52-Week High range of $9.46 and 52-week ...and more »
06/01/16 08:45 AMChemoCentryx Reports Received EMA PRIME Designation for Accelerated Assessment of CCX168 for Treatment of Patients with ANCA-Associated Vasculitis - ChemoCentryx, Inc., (Nasdaq: CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced it received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for CCX168 for the treatment of ANCA-Associated Vasculitis, or AAV. As described by the EMA, PRIME aims to bring promising innovative medicines to patients faster by optimizing and supporting medicine development. To be accepted for PRIME, a medicine has to show its potential to benefit patients with unmet medical needs based on clinical data. ChemoCentryx had previously received orphan drug status in Europe for CCX168 for use in the two main forms of AAV, namely granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). In the newly conferred PRIME designation, EMA acknowledged that GPA and MPA are highly severe diseases, and that the safety profiles of the existing treatments are not optimal. Mortality at one year exceeds 15% and the predominant causes of early death are infection and active vasculitis. This, together with the ...Full story available on Benzinga.com
06/01/16 07:30 AMChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis - [GlobeNewswire] - MOUNTAIN VIEW, Calif., June 01, 2016-- ChemoCentryx, Inc.,, a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, ...
05/31/16 08:50 PMChemoCentryx Inc. (CCXI) Jumps 17.65% on May 30 - Equities.com - ChemoCentryx Inc. (CCXI) Jumps 17.65% on May 30Equities.comChemoCentryx Inc. (CCXI) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 17.65% to $5.20, representing a gain of $0.78 per share. Some 3.66 million shares traded hands on 10,895 trades, compared with an ...and more »
05/31/16 03:09 PMAttention Grabbing Stocks of Healthcare: ChemoCentryx Inc (NASDAQ:CCXI), Pacific Biosciences of California ... - The Point Review - The Point ReviewAttention Grabbing Stocks of Healthcare: ChemoCentryx Inc (NASDAQ:CCXI), Pacific Biosciences of California ...The Point ReviewShares of ChemoCentryx Inc (NASDAQ:CCXI) flew 4.04% to $5.41 at 12:31 PM EDT. The stock attained the volume of 2.33 Million shares recently versus average trading volume of 2.25 Million shares. If we take a look on its volatility, 13.32 percent was ...and more »
05/30/16 05:01 PMChemoCentryx, Inc. (NASDAQ:CCXI) Boast 1-Year Price Target Of $13 - Investor Newswire - ChemoCentryx, Inc. (NASDAQ:CCXI) Boast 1-Year Price Target Of $13Investor NewswireAs of 2016-05-29, ChemoCentryx, Inc. (NASDAQ:CCXI) stock has an ABR of 3. This value was reached after accounting the price forecasts of 1 brokerages. The ABR mechanism encourages shareholders to invest in a stock which has a rating of '1'. Zacks has ...and more »
05/30/16 05:01 PMHC Stock Overview: ChemoCentryx Inc (NASDAQ:CCXI), Bristol-Myers Squibb Co (NYSE:BMY) - share market updates (press release) - HC Stock Overview: ChemoCentryx Inc (NASDAQ:CCXI), Bristol-Myers Squibb Co (NYSE:BMY)share market updates (press release)Shares of ChemoCentryx Inc (NASDAQ:CCXI) ended Friday session in green amid volatile trading. The shares closed up +0.78 points or 17.65% at $5.20 with 3.66 million shares getting traded. Post opening the session at $4.41, the shares hit an intraday ...and more »
05/30/16 05:01 PMPositive Gainer of the last Week: ChemoCentryx, Inc.'s (CCXI) - Is stories - Is storiesPositive Gainer of the last Week: ChemoCentryx, Inc.'s (CCXI)Is storiesChemoCentryx, Inc.'s (CCXI) witnessed a gain of 17.65% in recent trading period with closing price of $ 5.20. The company's last traded volume of 3.66 million shares was above it's an average volume of 1.14 million shares. In the trailing 12 months ...and more »
05/28/16 04:57 PMChemoCentryx (CCXI) Pushes Into Positive Territory; Alphabet Inc. (GOOG, GOOGL) Outperforms on Judge’s Ruling - ChemoCentryx, Inc. (Nasdaq:CCXI) stock soared to touch the $5.60 mark throughout the course of Friday’s market activity, finally closing at $5.20, up $0.78 (or +17.65%) with a total volume of 3,659,838 shares traded during the day. There was no news ...
05/27/16 05:16 PMNoteworthy Friday Option Activity: ChemoCentryx Inc (NASDAQ:CCXI) - The Point Review - The Point ReviewNoteworthy Friday Option Activity: ChemoCentryx Inc (NASDAQ:CCXI)The Point ReviewShare of ChemoCentryx Inc (NASDAQ:CCXI) traded on 16.80 percent above secure line at 2:56PM EDT in order to take the company's stock at the price of $5.16. At the time of writing the stock exchanged hands 3.13 million shares versus average trading ...ChemoCentryx, Inc. (NASDAQ:CCXI) Analyst ReviewRisers & FallersChemoCentryx Inc (NASDAQ:CCXI)'s Company Shares Increased 81.15% After Low VolatilityThe Postall 4 news articles »
05/27/16 10:59 AMCHEMOCENTRYX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/25/16 04:58 PMTraders Checklist Stocks: ChemoCentryx, Inc. (NASDAQ:CCXI) , Ophthotech Corporation (NASDAQ:OPHT) - Street Updates - Traders Checklist Stocks: ChemoCentryx, Inc. (NASDAQ:CCXI) , Ophthotech Corporation (NASDAQ:OPHT)Street UpdatesChemoCentryx, Inc. (NASDAQ:CCXI) unchanged +0.00%, closing at $4.37 after floating between $4.20 and $4.47. The company has market capitalization of $193.55M. It has twelve month low of $1.92 and twelve month high of $9.46. The recent traded ...and more »
05/25/16 07:30 AMChemoCentryx to Present at the Jefferies 2016 Healthcare Conference - [GlobeNewswire] - MOUNTAIN VIEW, Calif., May 25, 2016-- ChemoCentryx, Inc.,, a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and ...
05/24/16 08:40 AMInvestor's Healthcare Focused Stocks: Baxalta Incorporated (NYSE:BXLT) , ChemoCentryx, Inc. (NASDAQ:CCXI) - Is stories - Is storiesInvestor's Healthcare Focused Stocks: Baxalta Incorporated (NYSE:BXLT) , ChemoCentryx, Inc. (NASDAQ:CCXI)Is storiesIn most recently trading session on 5/23/2016, ChemoCentryx, Inc. (NASDAQ:CCXI) climbed +2.10% while traded on 1.85 million shares versus it's an average volume of 1.11 million shares. The company recorded the last trade with the price of $4.37.and more »
05/24/16 08:40 AMChemoCentryx (CCXI) Present Positive Data from CCX168 Phase 2 in AAV - Claim your 2-week free trial to StreetInsider Premium here. ChemoCentryx, Inc., (Nasdaq: CCXI) announced the presentation of positive results from its Phase II CLEAR trial with CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA ...
05/23/16 09:50 AMRecent Movements of Stocks: Halozyme Therapeutics, Inc. (NASDAQ:HALO) , ChemoCentryx, Inc. (NASDAQ:CCXI) - Street Updates - Recent Movements of Stocks: Halozyme Therapeutics, Inc. (NASDAQ:HALO) , ChemoCentryx, Inc. (NASDAQ:CCXI)Street UpdatesOn 5/20/2016, Halozyme Therapeutics, Inc. (NASDAQ:HALO) ended trading session higher at $9.15 with +2.69%. The company traded a volume of 1.25 million shares as comparison to average volume of 1.79 million shares. During the 52 –week period, the ...
05/23/16 08:17 AM9:17 am ChemoCentryx presents 'positive' results from phase II ANCA-associated vasculitis Clear Trial of CCX168 at the 53rd Era-Edta Congress, trial met primary endpoint -
05/23/16 08:15 AMChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress - [GlobeNewswire] - --Treatment with CCX168 successful in achieving clinical efficacy endpoints while eliminating high-dose oral corticosteroids from current standard-of-care regimen, suggesting a new treatment paradigm for ...
05/20/16 10:07 PMHealthcare Stocks Movements : Baxalta Incorporated (NYSE:BXLT) , ChemoCentryx, Inc. (NASDAQ:CCXI) - Street Updates - Healthcare Stocks Movements : Baxalta Incorporated (NYSE:BXLT) , ChemoCentryx, Inc. (NASDAQ:CCXI)Street UpdatesIn the past trading session, ChemoCentryx, Inc. (NASDAQ:CCXI) highlighted downward shift of -8.39% or -0.40 points to $4.37. The company traded a volume of 4.22 million shares over average volume of 1.07 million shares. Trailing twelve month period ...and more »
05/20/16 10:07 PMBest Healthcare Stock: ChemoCentryx Inc (NASDAQ:CCXI) - News Oracle - News OracleBest Healthcare Stock: ChemoCentryx Inc (NASDAQ:CCXI)News OracleThe Company declined -8.39% and finished at $4.37. The daily volume was measured at 4.22 million shares. The 52-week high of the share price is $9.46 and the 52-week low is $1.92. The company has a market cap of $239.80 million. Its latest closing ...and more »
05/20/16 10:07 PMChemoCentryx Inc. (CCXI) Drops 8.39% on May 19 - Equities.com - ChemoCentryx Inc. (CCXI) Drops 8.39% on May 19Equities.comChemoCentryx Inc. (CCXI) was one of the Russell 2000's biggest losers for Thursday May 19 as the stock slid 8.39% to $4.37, a loss of $-0.4 per share. Starting at an opening price of $4.80 a share, the stock traded between $4.15 and $5.19 over the ...and more »
05/20/16 10:07 PMRevenue Update on ChemoCentryx Inc(NASDAQ:CCXI) - Trade Calls - Revenue Update on ChemoCentryx Inc(NASDAQ:CCXI)Trade CallsChemoCentryx Inc(NASDAQ:CCXI) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 10, 2016. Earnings per share were $-0.34. Analysts had estimated an EPS of $-0.27. ChemoCentryx Inc (CCXI) ...Chemocentryx, Inc. (CCXI) Files Form 4 Insider Buying : Thomas A. Edwards Buys 50000 SharesMarket Digestall 2 news articles »
05/20/16 08:31 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: ChemoCentryx Inc (NASDAQ: CCXI ... - Analyst Ratings - Analysts Have Conflicting Sentiments on These Healthcare Companies: ChemoCentryx Inc (NASDAQ: CCXI ...Analyst RatingsAnalysts have been eager to weigh in on the Healthcare sector with new ratings on ChemoCentryx Inc (NASDAQ: CCXI), SCYNEXIS Inc (NASDAQ: SCYX), Tesaro (NASDAQ: TSRO) and Summit Therapeutics PLC (NASDAQ: SMMT). ChemoCentryx Inc ...
05/20/16 08:30 AMChemoCentryx Inc. (CCXI) is Trading Higher on Unusual Volume for May 18 - Equities.com - ChemoCentryx Inc. (CCXI) is Trading Higher on Unusual Volume for May 18Equities.comChemoCentryx Inc. (CCXI) experienced unusually high volume on May. 18, as the stock gained 23.9% to a closing price of $4.77. The stock saw 3.29 million shares trade hands over the course of the day on 9,079 trades. Given that the stock's average daily ...and more »
05/19/16 05:03 PMStocks inside Analysts Spotlight: Hologic, Inc. (NASDAQ:HOLX) , ChemoCentryx, Inc. (NASDAQ:CCXI) - Street Updates - Stocks inside Analysts Spotlight: Hologic, Inc. (NASDAQ:HOLX) , ChemoCentryx, Inc. (NASDAQ:CCXI)Street UpdatesHologic, Inc. (NASDAQ:HOLX) decreased -0.86% or -0.29 points. The company traded volume of 5.99 million shares more than average volume of 3.9 million shares. It has the market value of $9.28B and its EPS ratio for the past year is recorded at 0.71.and more »
05/19/16 12:04 PMCHEMOCENTRYX, INC. Financials -
05/19/16 08:17 AMManufacturing: Gainers and Decliners, at the Close - Chemocentryx Inc (CCXI)- The company’s stocks gained 23.9 pct. Aerie Pharmaceutical (AERI)- The company’s stocks surged 14.1 pct. Spark Therap Cmn (ONCE)- The company’s stocks gained 11.07 pct. Icad Inc Cmn Stk (ICAD)- The company’s stocks surged 9 ...
05/18/16 10:08 PMChemoCentryx Inc. (CCXI) Jumps 23.9% on May 18 - Equities.com - ChemoCentryx Inc. (CCXI) Jumps 23.9% on May 18Equities.comChemoCentryx Inc. (CCXI) was among the biggest gainers on the Russell 2000 for Wednesday May 18 as the stock popped 23.9% to $4.77, representing a gain of $0.92 per share. Some 3.29 million shares traded hands on 9,079 trades, compared with an ...and more »
05/18/16 05:00 PMStocks within investor Spotlight: ChemoCentryx, Inc. (NASDAQ:CCXI) , EXACT Sciences Corporation (NASDAQ:EXAS) - Street Updates - Stocks within investor Spotlight: ChemoCentryx, Inc. (NASDAQ:CCXI) , EXACT Sciences Corporation (NASDAQ:EXAS)Street UpdatesChemoCentryx, Inc. (NASDAQ:CCXI) diminished -4.47%, closing at $3.85 after floating between $3.76 and $4.26. The company has market capitalization of $170.52M. It has twelve month low of $1.92 and twelve month high of $9.46. The recent traded volume ...and more »
About ChemoCentryx

ChemoCentryx logoChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company's pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CCXI
  • CUSIP: 16383L10
Key Metrics:
  • Previous Close: $4.52
  • 50 Day Moving Average: $4.62
  • 200 Day Moving Average: $4.11
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $200.19M
  • Current Quarter EPS Consensus Estimate: $-0.35 EPS
Additional Links:
ChemoCentryx (NASDAQ:CCXI) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha